FY2024 EPS Estimates for Viking Therapeutics, Inc. Cut by SVB Leerink (NASDAQ:VKTX)

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Rating) – Equities research analysts at SVB Leerink lowered their FY2024 EPS estimates for shares of Viking Therapeutics in a report issued on Tuesday, May 16th. SVB Leerink analyst T. Smith now expects that the biotechnology company will post earnings per share of ($1.16) for the year, down from their prior forecast of ($1.14). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($0.87) per share. SVB Leerink also issued estimates for Viking Therapeutics’ FY2025 earnings at ($1.79) EPS, FY2026 earnings at ($2.25) EPS and FY2027 earnings at ($2.47) EPS.

Viking Therapeutics (NASDAQ:VKTX – Get Rating) last released its earnings results on Wednesday, April 26th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01).

Several other equities analysts also recently weighed in on the company. HC Wainwright increased their target price on Viking Therapeutics from $21.00 to $33.00 in a research report on Thursday, April 27th. Truist Financial boosted their target price on shares of Viking Therapeutics from $28.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, March 29th. Maxim Group increased their target price on Viking Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, March 28th. Roth Mkm increased their target price on shares of Viking Therapeutics from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, March 29th. Finally, StockNews.com initiated coverage on shares of Viking Therapeutics in a research report on Thursday. They set a “sell” rating on the stock. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $30.25.

Viking Therapeutics Stock Performance

VKTX stock opened at $22.97 on Friday. Viking Therapeutics has a one year low of $2.02 and a one year high of $25.03. The stock has a market capitalization of $2.29 billion, a P/E ratio of -24.18 and a beta of 0.78. The company has a 50 day moving average price of $17.93 and a two-hundred day moving average price of $11.17.

Insider Buying and Selling at Viking Therapeutics

In other Viking Therapeutics news, Director Lawson Macartney sold 20,786 shares of Viking Therapeutics stock in a transaction that occurred on Monday, April 17th. The stock was sold at an average price of $20.00, for a total transaction of $415,720.00. Following the sale, the director now directly owns 47,965 shares in the company, valued at approximately $959,300. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Charles A. Rowland, Jr. sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 16th. The stock was sold at an average price of $25.00, for a total value of $1,000,000.00. Following the sale, the director now owns 30,000 shares of the company’s stock, valued at approximately $750,000. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Lawson Macartney sold 20,786 shares of the firm’s stock in a transaction on Monday, April 17th. The shares were sold at an average price of $20.00, for a total value of $415,720.00. Following the completion of the sale, the director now owns 47,965 shares in the company, valued at $959,300. The disclosure for this sale can be found here. Insiders sold a total of 760,569 shares of company stock valued at $14,598,069 in the last ninety days. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Viking Therapeutics

Institutional investors have recently bought and sold shares of the stock. Quantum Private Wealth LLC boosted its position in shares of Viking Therapeutics by 0.8% in the 1st quarter. Quantum Private Wealth LLC now owns 65,048 shares of the biotechnology company’s stock valued at $1,083,000 after purchasing an additional 500 shares during the period. Sei Investments Co. grew its stake in Viking Therapeutics by 0.9% in the first quarter. Sei Investments Co. now owns 66,575 shares of the biotechnology company’s stock valued at $1,108,000 after purchasing an additional 605 shares in the last quarter. Moody Aldrich Partners LLC increased its holdings in Viking Therapeutics by 0.4% in the first quarter. Moody Aldrich Partners LLC now owns 203,826 shares of the biotechnology company’s stock worth $3,394,000 after buying an additional 907 shares during the last quarter. Financial Insights Inc. raised its holdings in shares of Viking Therapeutics by 7.1% during the 1st quarter. Financial Insights Inc. now owns 15,000 shares of the biotechnology company’s stock valued at $250,000 after purchasing an additional 1,000 shares in the last quarter. Finally, Advisor Group Holdings Inc. boosted its holdings in Viking Therapeutics by 1.0% in the fourth quarter. Advisor Group Holdings Inc. now owns 147,904 shares of the biotechnology company’s stock worth $1,390,000 after purchasing an additional 1,466 shares in the last quarter. Institutional investors and hedge funds own 34.71% of the company’s stock.

Viking Therapeutics Company Profile

(Get Rating)

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.